Παρασκευή 21 Απριλίου 2017

Nivolumab produces durable responses & long-term survival in severe liver cancer patients

Results from the CheckMate 040 study presented today found that nivolumab, an immuno-oncology drug which acts by modulating the immune system, produces durable responses with long-term survival rates, regardless of whether or not patients were infected...

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2pYQ8bl
via IFTTT

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Δημοφιλείς αναρτήσεις